Sydney 26th May 2023: Nyrada Inc (ASX: NYR), a preclinical stage, drug development company
specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, is
pleased to announce all of the preclinical Good Laboratory Practice (GLP) studies required by
the regulators to evaluate the safety and tolerability of its cholesterol-lowering drug candidate
were successfully completed at the end of April. The Company is on track to commence its
Phase I/IIa first-in-human study in early 2H CY2023.
Benny Boy, the cholesterol drug had completed all GLP studies!
It was past the point that NYR-BIO3 is currently at when it got pulled up.
I thought you said we had proven safety?!?!
Maybe they used lactose intolerant mice in the cholesterol studies? Can mice even be lactose intolerant?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.03M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1642 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 682527 | 2 |
View Market Depth
| Last trade - 07.10am 01/08/2025 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable